165 related articles for article (PubMed ID: 25041999)
1. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
[TBL] [Abstract][Full Text] [Related]
2. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
3. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
de Wilt LH; Kroon J; Jansen G; de Jong S; Peters GJ; Kruyt FA
Crit Rev Oncol Hematol; 2013 Mar; 85(3):363-72. PubMed ID: 22944363
[TBL] [Abstract][Full Text] [Related]
7. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
9. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
[TBL] [Abstract][Full Text] [Related]
10. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
[TBL] [Abstract][Full Text] [Related]
12. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
13. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
Furfaro AL; Piras S; Passalacqua M; Domenicotti C; Parodi A; Fenoglio D; Pronzato MA; Marinari UM; Moretta L; Traverso N; Nitti M
Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
[TBL] [Abstract][Full Text] [Related]
15. Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pawlak A; Conde B; Ochoa I; Fernández LJ; Anel A; Martinez-Lostao L
Recent Pat Anticancer Drug Discov; 2016; 11(2):197-214. PubMed ID: 26924736
[TBL] [Abstract][Full Text] [Related]
16. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
[TBL] [Abstract][Full Text] [Related]
17. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Eriksson E; Wickström M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Sävendahl L
J Natl Cancer Inst; 2014 Mar; 106(3):djt459. PubMed ID: 24586107
[TBL] [Abstract][Full Text] [Related]
18. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
Valentiner U; Haane C; Nehmann N; Schumacher U
Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Luo P; Lin M; Li L; Yang B; He Q
PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]